Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Szabo

Psychiatry Durham, NC Medical Doctor

NPI 1033352919 CMS profile 46881

2213 Elba St., Duke University Psychiatry Civitan Building, Rm 120, Durham, NC 27705

Open in the dashboard

General payments

$360,423

482 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$51,256 paid to institutions, not to them · program year 2019

Through program year 2025, Steven Szabo of Durham, NC is reported in the CMS Open Payments database as having received $360,423 across 482 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $51,256 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $108 2
2024 General $295 4
2023 General $153 2
2022 General $76 2
2021 General $38 2
2020 General $81 1
2019 General $359,673 469

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Szabo
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Steven Szabo were reported at $108. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Steven Szabo Psychiatry median Middle half National median
2019 $359,673 $184 $59–$605 $163
2020 $81 $119 $36–$372 $114
2021 $38 $143 $43–$576 $132
2022 $76 $153 $50–$590 $149
2023 $153 $170 $56–$651 $160
2024 $295 $179 $57–$673 $164
2025 $108 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neurocrine Biosciences, Inc. $104,920 167 payments
  2. Otsuka America Pharmaceutical, Inc. $104,365 142 payments
  3. Janssen Pharmaceuticals, Inc $78,513 74 payments
  4. Avanir Pharmaceuticals, Inc. $68,890 65 payments
  5. Otsuka Pharmaceutical Development & Commercialization, Inc. $2,693 6 payments
  6. Teva Pharmaceuticals USA, Inc. $335 11 payments
  7. ACADIA Pharmaceuticals Inc $157 4 payments
  8. Axonics Modulation Technologies, Inc. $153 2 payments
  9. Lundbeck LLC $137 5 payments
  10. AbbVie, Inc. $120 2 payments
  11. Other $140 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $312,462 121 payments
  2. Travel and Lodging $36,549 184 payments
  3. Food and Beverage $8,411 176 payments
  4. Consulting Fee $3,000 1 payment
Products named General payments · program years 2019–2025
  1. INGREZZA Neurology $104,651 164 payments
  2. REXULTI $104,412 144 payments
  3. SPRAVATO $78,262 72 payments
  4. NUEDEXTA $68,890 65 payments
  5. AUSTEDO $335 11 payments
  6. INGREZZA Neuropsychiatry $269 3 payments
  7. INVEGA SUSTENNA $251 2 payments
  8. INVEGA TRINZA $251 2 payments
  9. NUPLAZID $157 4 payments
  10. Bulkamid $153 2 payments
  11. Other $316 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$3,204

Medicare's payments for the services billed

Medicare patients

21

Average age 52

Services billed

51

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 62%
Atrial fibrillation 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $175
$175 — —
VRAYLAR
  • AbbVie, Inc. $93
$93 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

482 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record